10-Q: Quarterly report
Redemption Date Announced for Warrants
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference
No Decline in Cognition Scores in Patients With Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
Cassava Sciences, Inc. (NASDAQ:SAVA) Most Popular Amongst Retail Investors Who Own 59% of the Shares, Institutions Hold 31%